Bremer Trust National Association lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 28.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,584 shares of the medical technology company’s stock after purchasing an additional 1,009 shares during the period. Bremer Trust National Association’s holdings in Stryker were worth $719,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Northwest Wealth Management LLC increased its holdings in Stryker by 103.6% in the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 86 shares during the last quarter. Horan Securities Inc. purchased a new stake in Stryker in the 4th quarter worth about $30,000. Truehand Inc purchased a new stake in Stryker in the 4th quarter worth about $30,000. Moody National Bank Trust Division purchased a new stake in Stryker in the 4th quarter worth about $32,000. Finally, WESPAC Advisors SoCal LLC purchased a new stake in Stryker in the 4th quarter worth about $34,000. Institutional investors own 74.26% of the company’s stock.
Several equities research analysts recently weighed in on the company. Piper Jaffray Companies reissued an “overweight” rating and issued a $205.00 price objective on shares of Stryker in a report on Friday. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $195.00 price objective for the company in a report on Wednesday, December 5th. Oppenheimer set a $170.00 price objective on Stryker and gave the stock a “hold” rating in a report on Friday, November 9th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a report on Friday, November 9th. Finally, Deutsche Bank assumed coverage on Stryker in a report on Wednesday, January 2nd. They issued a “buy” rating and a $179.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Stryker currently has a consensus rating of “Buy” and a consensus target price of $186.26.
SYK stock opened at $189.74 on Friday. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. The stock has a market cap of $69.67 billion, a price-to-earnings ratio of 25.96, a P/E/G ratio of 2.32 and a beta of 0.86. Stryker Co. has a twelve month low of $144.75 and a twelve month high of $189.69.
Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.03. The business had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. Sell-side analysts expect that Stryker Co. will post 8.12 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date is Thursday, March 28th. Stryker’s payout ratio is presently 28.45%.
In other news, COO Timothy J. Scannell sold 4,666 shares of Stryker stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $186.25, for a total transaction of $869,042.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 180 shares of Stryker stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $176.77, for a total value of $31,818.60. The disclosure for this sale can be found here. Insiders have sold a total of 47,925 shares of company stock valued at $8,384,790 in the last ninety days. Insiders own 7.30% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: What is cost of equity?